Universitätsklinikum Schleswig-Holstein (UKSH)

Analysis of factors contributing to variation in the C57BL/6J fecal microbiota across German animal facilities (2016) Günther C, Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, et al. Journal article Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): Study protocol for a randomized controlled trial (2016) Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff SC, Dukatz R, Siniatchkin M, et al. Journal article Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer (2016) Wenners A, Hartmann F, Jochens A, Roemer AM, Alkatout I, Klapper W, Van Mackelenbergh M, et al. Journal article Hartgewebeaugmentationen: Materialwahl (2016) Schlegel KA, Wiltfang J, Lutz R, Schmitt C, Möst T Journal article Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey (2016) Van Mackelenbergh MT, Lindner CM, Heilmann T, Alkatout I, Elessawy M, Mundhenke C, Maass N, Schem C Journal article, Review article DISEASE PROGRESSION IN 282 PATIENTS WITH UNDIFFERENTIATED SSC - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLERODERMA (2016) Moinzadeh P, Blank N, Siegert E, Henes J, Susok L, Distler J, Juche A, et al. Conference contribution Targeted Intraoperative Radiation Therapy Tumor Bed Boost During Breast-Conserving Surgery After Neoadjuvant Chemotherapy in TNBC and HER2 Positive Breast Cancer (2016) Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Liedtke C, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, et al. Conference contribution